paroxetine has been researched along with Refractory Depression in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Croarkin, PE; Mills, JA; Strawn, JR | 1 |
| Cao, L; Chen, J; Fang, Y; Hong, W; Peng, D; Wu, Z; Yuan, C; Zhang, C | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, GN; Emslie, GJ; He, J; Hilton, RC; Keller, MB; Mansoor, B; Mayes, T; Porta, G; Rengasamy, M; Ryan, N; Shamseddeen, W; Wagner, KD | 1 |
| Jia, HX; Liu, J; Shi, J; Tian, JZ; Wang, JQ; Xu, Y | 1 |
| Birmaher, B; Brent, D; Clarke, G; Emslie, GJ; He, J; Hilton, R; Mansoor, B; Mayes, TL; Porta, G; Rengasamy, M; Ryan, N; Shamseddeen, W; Spirito, A; Wagner, KD | 1 |
| Benetti, F; Blandina, P; Cassano, T; Corradetti, R; Galeotti, N; Munari, L; Passani, MB; Provensi, G | 1 |
| Pan, PY; Yeh, CB | 1 |
| Datka, W; Dudek, D; Gurwitz, D; Kmiotek, K; Obuchowicz, M; Oved, K; Pilc, A; Rzezniczek, S; Shomron, N; Siwek, M | 1 |
| Barbee, JG; Conrad, EJ; Jamhour, NJ; Reimherr, FW; Shelton, RC; Stewart, JW; Thompson, PM; Thompson, TR | 1 |
| Boku, S; Fujisawa, D; Honda, M; Inoue, T; Ishikane, T; Ito, K; Kawamura, K; Koyama, T; Matsubara, R; Ono, Y; Sasaki, K; Shinohara, K; Suzuki, T; Tsuchiya, K | 1 |
| Hori, H; Ikenouchi-Sugita, A; Iwata, N; Katsuki, A; Kishi, T; Nakamura, J; Umene-Nakano, W; Yoshimura, R | 1 |
7 trial(s) available for paroxetine and Refractory Depression
| Article | Year |
|---|---|
Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Buspirone; China; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Remission Induction; Risperidone; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2013 |
Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
Topics: Adolescent; Anxiety; Attention Deficit and Disruptive Behavior Disorders; Behavioral Symptoms; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Fluoxetine; Humans; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
[Treatment of refractory depression patients of yin deficiency inner heat syndrome by jieyu granule combined paroxetine: an efficacy observation].
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Treatment-Resistant; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Paroxetine; Phytotherapy; Treatment Outcome; Yin Deficiency | 2013 |
The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Body Mass Index; Child; Citalopram; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lamotrigine; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Severity of Illness Index; Triazines | 2011 |
Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Administration Schedule; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Sertraline; Severity of Illness Index; Treatment Outcome | 2012 |
Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Sertraline | 2012 |
4 other study(ies) available for paroxetine and Refractory Depression
| Article | Year |
|---|---|
Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
Topics: Adolescent; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Fluoxetine; Humans; Monte Carlo Method; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2019 |
Brain Histamine Is Crucial for Selective Serotonin Reuptake Inhibitors' Behavioral and Neurochemical Effects.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Antidepressive Agents; Brain; Citalopram; Cyclic AMP Response Element-Binding Protein; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; Female; Histamine; Histidine Decarboxylase; Male; Methylhistidines; Methysergide; Mice, Knockout; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2015 |
Laughter therapy in a geriatric patient with treatment-resistant depression and comorbid tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Laughter Therapy; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tardive Dyskinesia | 2016 |
Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients.
Topics: Adult; Biomarkers; Cell Proliferation; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Integrin beta3; Male; Mianserin; Middle Aged; Mirtazapine; Monocytes; Paroxetine; Peptide Fragments; Serotonin Plasma Membrane Transport Proteins | 2016 |